Monday, 10 August 2020


Oramed recruits patients for oral insulin trial

22 August 2013 | News | By BioSpectrum Bureau

Singapore: Oramed Pharmaceuticals initiated patient recruitment for a new clinical trial of its orally ingestible insulin capsule,ORMD-0801, for patients with type 1 diabetes mellitus (T1DM) in Israel.

Earlier clinical studies have shown that ORMD-0801 administered to T1DM patients just prior to a meal, effectively kept their blood sugar levels stable. The results of one such trial were published earlier this year in the international, peer-reviewed journal PLOS ONE.

The research article is titled, 'Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study'.

Mr Nadav Kidron, CEO, Oramed, "We are very excited to continue our development of ORMD-0801 for this high-need indication. We have been encouraged by our successful T1DM trials to date and we look forward to the commencement of this study."


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls